UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A tribute to Fanconi: ‘clinical acumen still counts’

Haematologica (Roma), 2023-01, Vol.108 (1), p.1-2

2023

Volltextzugriff (PDF)

Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria

Haematologica (Roma), 2021-12, Vol.106 (12), p.3188-3197

2021

Volltextzugriff (PDF)

Complement Mediated Hemolytic Anemias in the COVID-19 Era: Case Series and Review of the Literature

Frontiers in immunology, 2021-11, Vol.12, p.791429

2021

Volltextzugriff (PDF)

Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome

Blood, 2014-10, Vol.124 (17), p.2698-2704

2014

Volltextzugriff (PDF)

Terminal complement inhibition dampens the inflammation during COVID‐19

British journal of haematology, 2020-08, Vol.190 (3), p.e141-e143

2020

Volltextzugriff (PDF)

Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia

Leukemia, 2021-11, Vol.35 (11), p.3223-3231

2021

Volltextzugriff (PDF)

Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome

Leukemia, 2019-10, Vol.33 (10), p.2495-2505

2019

Volltextzugriff (PDF)

Management of the refractory aplastic anemia patient: what are the options?

Blood, 2013-11, Vol.122 (22), p.3561-3567

2013

Volltextzugriff (PDF)

SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment

Nature communications, 2015-12, Vol.6 (1), p.10004, Article 10004

2015

Volltextzugriff (PDF)

SARS-CoV-2 infection in aplastic anemia

Haematologica (Roma), 2022-02, Vol.107 (2), p.541-543

2022

Volltextzugriff (PDF)

AI for AA: machine learning makes an entry

Blood, 2023-04, Vol.141 (17), p.2040-2042

Kulasekararaj, Austin G.

2023

Volltextzugriff (PDF)

The Effect of Respiratory Viral Infections on Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria

International journal of molecular sciences, 2023-05, Vol.24 (11), p.9358

2023

Volltextzugriff (PDF)

Editorial: Immunologic Mechanisms of Myeloid Neoplasms

Frontiers in oncology, 2022-06, Vol.12, p.949633-949633

2022

Volltextzugriff (PDF)

Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes

British journal of haematology, 2013-09, Vol.162 (5), p.587-605

2013

Volltextzugriff (PDF)

The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome

Haematologica (Roma), 2013-08, Vol.98 (8), p.1196-1205

2013

Volltextzugriff (PDF)

Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria

Haematologica (Roma), 2024-03, Vol.109 (3), p.929

2024

Volltextzugriff (PDF)

Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation

Haematologica (Roma), 2014-10, Vol.99 (10), p.1574-1581

2014

Volltextzugriff (PDF)

Concomitant Immunosuppressive Therapy and Eculizumab Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Analysis

Acta haematologica, 2023-01, Vol.146 (1), p.1-14

2023

Volltextzugriff (PDF)

Chronic relapsing remitting Sweet syndrome – a harbinger of myelodysplastic syndrome

British journal of haematology, 2015-09, Vol.170 (5), p.649-656

2015

Volltextzugriff (PDF)

Paroxysmal nocturnal hemoglobinuria: Where are we going

American journal of hematology, 2023-05, Vol.98 (S4), p.S33-S43

2023

Volltextzugriff (PDF)

Eltrombopag in Lower-Risk Myelodysplastic Syndrome: Revival of Its Use in Thrombocytopenia

Journal of clinical oncology, 2023-10, Vol.41 (28), p.JCO2301141-4468

2023

Volltextzugriff (PDF)

Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome

Haematologica (Roma), 2013-07, Vol.98 (7), p.1058-1066

2013

Volltextzugriff (PDF)

Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag

Haematologica (Roma), 2019-11, Vol.104 (11), p.e494-e496

2019

Volltextzugriff (PDF)

1 – 25 von 178

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(169)
Mit Volltextzugriff
(156)

Publikationsform

Sprache

Englisch
(178)

Erscheinungsjahr

n.n

Thema

Science & Technology
(102)
Life Sciences & Biomedicine
(98)
Humans
(82)
Hematology
(77)
Male
(45)
Female
(43)
Adult
(40)
Middle Aged
(33)
Aged
(26)
Paroxysmal Nocturnal Hemoglobinuria
(23)
Hemoglobinuria, Paroxysmal - Drug Therapy
(19)
Treatment Outcome
(19)
Aged, 80 And Over
(17)
Anemia
(16)
Myelodysplastic Syndromes - Genetics
(16)
Young Adult
(16)
Adolescent
(15)
Oncology
(15)
Patients
(15)
Mutation
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A tribute to Fanconi: ‘clinical acumen still counts’

Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria

Complement Mediated Hemolytic Anemias in the COVID-19 Era: Case Series and Review of the Literature

Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome

Terminal complement inhibition dampens the inflammation during COVID‐19

Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia

Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome

Management of the refractory aplastic anemia patient: what are the options?

SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria

SARS-CoV-2 infection in aplastic anemia

AI for AA: machine learning makes an entry

The Effect of Respiratory Viral Infections on Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria

Editorial: Immunologic Mechanisms of Myeloid Neoplasms

Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes

The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome

Current use of androgens in bone marrow failure disorders: a report from the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation

Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria

Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation

Concomitant Immunosuppressive Therapy and Eculizumab Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Analysis

Chronic relapsing remitting Sweet syndrome – a harbinger of myelodysplastic syndrome

Paroxysmal nocturnal hemoglobinuria: Where are we going

Eltrombopag in Lower-Risk Myelodysplastic Syndrome: Revival of Its Use in Thrombocytopenia

Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome

Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag

Suchergebnisse filtern